Catalyst Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Catalyst Pharmaceuticals (CPRX) Tops Q3 EPS by 2c, Offers FY19 and FY20 Guidance
November 12, 2019 4:41 PM ESTCatalyst Pharmaceuticals (NASDAQ: CPRX) reported Q3 EPS of $0.13, $0.02 better than the analyst estimate of $0.11. Revenue for the quarter came in at $30.9 million versus the consensus estimate of $33.18 million.
GUIDANCE:
Catalyst Pharmaceuticals sees FY2019 revenue of $100 million, versus the consensus of $111... More
